Background: We previously demonstrated the local production of the pleiotropic cytokine interleukin-6 (IL-6) in the central nervous system (CNS) in experimental autoimmune encephalomyelitis (EAE), an animal model for the human disease multiple sclerosis. Materials and Methods: To assess the role of IL-6 in autoimmune CNS inflammation, we administered neutralizing antibodies to IL-6 in the EAE model. Their effect was examined at the clinical and histopathological level. Levels of administered antibody and IL-6 bioactivity were followed in serum and cerebrospinal fluid (CSF). Results: Systemically administered antibodies penetrated into the fluid CSF in animals in which EAE was induced. Administration of anti-IL-6 reduced the development of actively induced as well as adoptively trans-
INTRODUCTION
Interleukin-6 (IL-6) is a pleiotropic cytokine which is present during inflammation (1) . Elevated IL-6 levels are found in vivo in almost every infectious and/or inflammatory condition. is detectable in the cerebrospinal fluid (CSF) ferred EAE and was associated with increased levels of IL-6 activity in the CSF and to a lesser extent in the serum. Anti-IL-6 was still effective when given 1 day before the onset of disease signs in adoptively transferred EAE. The disease-reducing effect of anti-IL-6 was also reflected at the pathological level by the absence of inflammatory infiltrates in the CNS. Conclusions: Our study indicates that IL-6 plays an important role in autoimmune CNS inflammation. However, due to the complex nature of the in vivo interactions of administered antibodies, the disease-reducing effect of the anti-IL-6 antibodies could be caused by neutralization of IL-6 activity or by enhancement of IL-6 activity via induction of higher IL-6 levels in the CNS. during viral, bacterial, and fungal infections of the central nervous system (CNS) in humans, and in experimental viral infection of the CNS in animals (2) (3) (4) (5) . Elevated levels of IL-6 are also detectable in various diseases in which autoimmunity may play a role, such as rheumatoid arthritis (6) and lupus erythematosus (7) . But, little if any IL-6 has been detected in the CSF of multiple sclerosis (MS) patients (2, 3, 8, 9) , although MS is also considered to be of autoim-796 Molecular Medicine, Volume 1, Number 7, November 1995 mune origin. Surprisingly, two groups found that IL-6 levels in the circulation of MS patients were frequently elevated and were higher than levels in CSF (5, 10) . In diseases in which inflammation is mainly limited to a well-defined compartment of the body (e.g., joint or meningeal space), IL-6 levels are typically much higher locally than in the serum, suggesting local production of the cytokine and subsequent release into the bloodstream. We previously reported IL-6 production in the CNS of animals that were developing experimental autoimmune encephalomyelitis (EAE), an animal model for autoimmune inflammation of the CNS (11) . Elevated IL-6 levels in EAE are associated with disease onset, as in other inflammatory CNS disorders (12) . Possible explanations for the discordance between the findings in MS and EAE could be that IL-6 is only produced in MS when the disease is initiated or during periods of lesion formation, making sampling time critical. In addition, produced locally in the lesions may not reach the CSF. The detection of IL-6 immunoreactivity in microglial cells and in reactive astrocytes in active MS plaques supports the latter hypothesis (13) .
IL-6 is an important mediator in various immunological and inflammatory processes that play a role in the pathogenesis of CNS disorders such as MS (e.g., stimulation of T cell-mediated immunity and local antibody production). IL-6 has both pro-and anti-inflammatory effects (14) . The net in vivo effect and role of IL-6 are difficult to predict because of its pleiotropic nature. In the present study we used neutralizing mAb to IL-6 to examine the role of IL-6 in the pathogenesis of EAE and to evaluate the potential use of anti-IL-6 therapy in inflammatory CNS disorders. 
MATERIALS AND METHODS

Sampling
Mice were sacrificed by CO2 inhalation. Blood was taken via cardiac puncture, whereafter it was allowed to clot and serum was separated by centrifugation. After incision of the skin over the neck and dissection of the underlying muscles, CSF was taken by puncture of the meninges between the occiput and first vertebra, avoiding the blood vessels (2-5 pl1/mouse) (15) . Samples visibly contaminated with blood were discarded. CSF was centrifuged and the supernatant taken.
When the samples had to be used for the IL-6 bioassay, the whole procedure was performed aseptically. During this procedure the samples were kept on ice. All samples were stored at -20°C until assayed.
Ab Treatment Rat mAb to murine rIL-6 (20F3) (16) Serum IL-6 levels were 5-fold higher in animals 36 hr after EAE-induction (23 U/ml) than in noninduced animals (4 U/ml) (Fig. 4A) . Administration of mAb to IL-6 increased these levels to up to 67500 U/ml. IL-6 levels were even increased in noninduced animals when given anti-IL-6 (10 U/ml). IL-6 levels were still increased at the onset of EAE (58 U/ml) and administration of anti-IL-6 increased them a further 10-fold (501 U/ml).
CSF levels of the cytokine were elevated in animals in which EAE had been induced, whether or not animals were diseased (Fig. 3  and 4B ). Levels of IL-6 in animals with EAE were almost 20 times higher after administration of anti-IL-6 (24000 U/ml, compared with 1380 U/ml in animals that received PBS). It should be noted that the mean disease score in the animals immunized to develop EAE, but treated with anti-IL-6 on Day -1, was 0 when CSF was sampled, compared with 2.0 in the PBS group and 1.33 in the animals treated with anti-IL-6 on Day 8. When anti-IL-6 was given on Day 8, IL-6 levels in serum and CSF were also increased, although serum levels were 3 to 10 times lower than in animals in which anti-IL-6 was given on Day -1.
A similar pattern for IL-6 levels, albeit lower, was observed in serum and CSF of animals 3 days after the onset of disease signs. Anti-,3-galactosidase did not significantly affect the IL-6 levels. Addition of mAb to IL-6 in the bioassay completely blocked all activity in serum (<3 U/ml) and CSF (<30 U/ml) samples from animals treated with PBS or with anti-IL-6.
Rat IgGI Levels in Serum and CSF Rat IgG 1 levels were determined on samples from an experiment similar to the one depicted in Fig. 4 (Table 3 ). All animals were sampled at the time of disease onset in the PBS-treated group. Rat IgGI, administered on Day 8, was detectable and reached comparable levels in the serum, independent of the nature of the mAb (anti-IL-6 or anti-13-galactosidase) or the clinical condition of the animals (normal or EAE). When administered on Day -1, serum levels were much lower or fell below detection limit. Rat IgGI was only detectable in the CSF of animals in which EAE was induced, irrespective of the nature of the mAb or the clinical condition of the animals. Levels were just above detection limit (1 jig/ml) when the mAb was given on Day -1, and 3 times higher when given on Day 8 (approximately 1-2% of the serum levels).
DISCUSSION
We administered neutralizing mAb to IL-6 in animals in which EAE was induced to evaluate the role of this pleiotropic cytokine in inflammatory CNS disorders of autoimmune origin. Administration of the mAb significantly reduced the development of EAE, both in actively induced EAE and in the adoptive transfer model of EAE. A single dose of mAb was sufficient to cause this effect, and could be given as late as one day before the onset of clinical signs in the adoptively transferred model, although administration of the mAb around the time of disease induction was most effective in both EAE models. This demonstrates that the mAb is not only acting on the induction phase, but also on the effector phase of the disease (i.e., the inflammatory reaction in the CNS). In actively induced EAE, however, administration on Day 7 or 8 after induction was ineffective, whereas administration on Day -1 was effective (clinical disease onset from Day 9-12). Moreover, the absence of inflammatory infiltrates in the CNS of animals in which EAE was actively induced and that were treated with mAb to IL-6, demonstrates that the protective effect of anti-IL-6 on the clinical disease was also evident at the histopathological level. Anti-IFN,y was used as a positive control for anticytokine therapy in EAE, and had the diseaseenhancing effect that has been described previously (19) .
Several animals died within 6 hr after the second dose of Ab (rat anti-IL-6 mAb, rat anti-13-galactosidase mAb, or rat IgG). Since Relationship between levels of IL-6 and anti-IL-6 Ab in serum and CSF, and EAE expression IL-6 and anti-IL-6 Ab data are from Fig. 4 and Table 3 . The data regarding IL-6 levels and clinical and histological disease are from the same experiment. EAE was scored clinically as described in Materials and Methods. Histology was scored as either + or -, depending on the presence or absence, respectively, of inflammatory infiltrates and demyelination in the CNS. n.d., not determined.
was induced by transfer, where no pertussis toxin is given, and that also received multiple Ab doses never had this reaction.
Protective effects of anti-IL-6 have been described in several in vivo models of autoimmune or other inflammatory conditions, including autoimmune diabetes (21), systemic lupus erythematosus (22) , tumor necrosis factor (TNF) effects (23), endotoxin-induced shock and Shwartzman reaction (24) , and Toxoplasma gondii-infection of the CNS (25, 26) . The conclusion from these studies is that Abs to IL-6 are protective by neutralizing endogenous IL-6 activity, and hence that IL-6 has a pro-inflammatory effect in these models. However, there have been reports of increased levels of circulating IL-6 after administration of mAb to IL-6 in animals in which IL-6 production was induced (24, 26, 27) and in a patient with plasma cell leukemia after anti-IL-6 treatment (28). We found increased levels of IL-6 bioactivity in serum of animals treated with mAb to IL-6. In normal animals there was a slight increase in IL-6 levels, but levels were far more increased in animals that already had elevated IL-6 levels 36 hr after active EAE induction or at the onset of EAE. In addition, we could also demonstrate increased IL-6 levels in the CSF of animals treated with anti-IL-6, but only in animals in which EAE was induced and that already had elevated IL-6 levels in their CSF when disease started. levels in the CSF were increased to the same extent in animals that received anti-IL-6 on Day -1 and in animals that received them on Day 8. Only the former were protected clinically and histopathologically against the development of EAE, indicating that-at least in the actively induced EAE model-anti-IL-6 Abs must be present before Day 8 , and that mere elevated IL-6 levels in the CSF are not sufficient to prevent EAE (Fig. 3) . Addition of the 20F3 mAb (specific for murine IL-6) to the B9 bioassay completely blocked all IL-6 bioactivity in sera and CSF from animals in which EAE was induced (anti-IL-6-treated as well as nontreated animals), thereby proving that the biological activity detected could indeed be attributed to IL-6.
Increased IL-6 levels in the body fluids of anti-IL-6-treated mice may be due to delayed elimination and/or increased production. Complex formation with Ab may slow down the elimination of IL-6. Neutralization by Ab could reduce the biological availability of IL-6 and hence reduce the negative feedback that IL-6 may exert over its own production. It has been shown that in vivo administration of anti-IL- 6 Ab, in cases where there is elevated IL-6 production, induces circulating IL-6-Ab complexes that are biologically active in the HGF-assay (27) (28) (29) and Ab are present in equimolar concentrations and are nearly 100% complexed (29) . We did not examine whether the IL-6 was complexed when present in the CSF after mAb treatment, but the molar concentration of mAb could roughly be estimated to exceed that of IL-6 by a factor of 10 to 30. IL-6 complexed to anti-IL-6 Ab is known to retain its biological activity in the IL-6-bioas- aSerum levels from individual mice are shown, the mean is given in parentheses where appropriate.
bCSF levels are from pooled CSF (n = 3/group).
say: the affinity of the IL-6 receptor on the cell line used for the HGF-assay is higher than that of the Ab, and therefore IL-6 is still active on the cell line despite its binding to the Ab. This is also reflected in the excess of Ab to IL-6 necessary for in vitro neutralization of . It is unknown whether the higher levels of IL-6 that accumulate as IL-6-Ab complexes, also induce higher in vivo bioactivity of IL-6. Administration of IL-6-mAb complexes in a molar ratio of 1-2:1 augments some of the biological effects of IL-6 in vivo (27, 33 
